What is BBOT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BBOT?

P/E (TTM) is n/a and 52-week range is $3.27 to $14.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BBOT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BBOT?

The company profile lists net income (TTM) near $-244M, EPS (TTM) near $-3.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is BridgeBio Oncology Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 80.1M shares outstanding, ISIN US1079241022 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

BridgeBio Oncology Therapeutics Inc

$BBOT

Health Care · Biotechnology

Run Scenarios

$3.31

-3.22%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Website

bbotx.com/

IPO

2024-02-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)